When GLP‑1s stall
- Physicians say GLP‑1 medications sometimes fail to produce expected weight loss for genetic and other individual reasons. (womansworld.com) - The article lists possible causes and suggests alternative strategies patients can try when progress stalls. (womansworld.com) - Doctors recommend evaluating genetics, expectations, and alternative treatments if a patient isn't losing weight on GLP‑1s. (womansworld.com)
Glucagon-like peptide 1 drugs can curb appetite and slow stomach emptying, but they do not produce the same weight loss in every patient. In the pivotal Wegovy trial, adults taking semaglutide 2.4 milligrams lost an average of about 14.9% of body weight at 68 weeks, not 14.9% every time or in every person. Zepbound’s label reports larger average losses over 72 weeks with tirzepatide, but it also tells prescribers to weigh “treatment response and tolerability” when choosing a maintenance dose. Doctors treat that spread in results as expected variation, not proof that a drug “stopped working.” A 2026 Nature study of 27,885 people on glucagon-like peptide 1 medicines found substantial person-to-person differences and linked some of that variation to genetic differences in the GLP1R and GIPR pathways. Weight loss itself also slows over time because a smaller body burns fewer calories, and obesity treatment is built around longer-term management rather than a straight line down on the scale. The National Institute of Diabetes and Digestive and Kidney Diseases says clinicians should set individualized goals, with 5% of body weight over 6 months offered as one example of an initial target. That gap between trial averages and individual results matters because obesity is common and chronic: more than 4 in 10 U.S. adults have obesity, according to the same agency. NIDDK says medicines are used as part of a broader weight-control program when eating and activity changes alone are not enough. A plateau can also reflect how the drug is being used. Wegovy and Zepbound both start at low weekly doses and step up over time, and Zepbound’s prescribing information says the maintenance dose should be selected based on response and side effects. Food quality and muscle-preserving habits still matter after the prescription is filled. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society said limited knowledge about nutrition and lifestyle measures can reduce glucagon-like peptide 1 treatment efficacy in real-world care. When progress stalls, the usual next step is not to declare failure but to reassess the plan: dose, side effects, adherence, diet, activity, sleep, other medicines, and whether another obesity treatment fits better. Federal guidance lists medicines, intensive behavioral programs, devices, and surgery as established options in obesity care.
